Comparison of immunohistochemistry (IHC) and quantitative RT-PCR: ER, PR, and HER2 receptor status
Abstract only 47 Background: IHC is the present standard for measuring estrogen (ER) and progesterone receptor (PR) expression for breast cancer. However, the lack of concordance between testing laboratories and the critical patient treatment decisions made with results prompted ASCO/CAP to recommen...
Saved in:
Published in | Journal of clinical oncology Vol. 30; no. 27_suppl; p. 47 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
20.09.2012
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract only
47
Background: IHC is the present standard for measuring estrogen (ER) and progesterone receptor (PR) expression for breast cancer. However, the lack of concordance between testing laboratories and the critical patient treatment decisions made with results prompted ASCO/CAP to recommend guidelines and proficiency testing requirements to ensure accuracy. Quantitative RT-PCR (qRT-PCR) is an alternative method for ER and PR testing and while concordance with IHC has been reported, additional testing is merited. This study compares ER, PR and HER2 status determined by IHC and qRT-PCR. Methods: FFPE tissues of ER(+) tumors collected and tested at the Blumenthal Cancer Center were studied. Expression levels of ESR1, PGR, and ERBB2 were determined by a multiplex qRT-PCR TaqMan assay and by the Oncotype Dx assay. Pre-established cutpoints were used to determine positivity. Only samples with qRT-PCR and corresponding IHC data were used, resulting in 144 ER, 128 PR, and 107 HER2 comparisons. ESR1 and PGR expression levels determined by the two qRT-PCR assays were also compared. Results: Of the144 IHC ER(+) samples, 142 were positive and 2 were negative by both qRT-PCR assays. All 120 IHC PR(+) samples were positive by both qRT-PCR assays. Of the 8 IHC PR(-) samples, 5 were negative and 3 were positive by both qRT-PCR assays. Of the 107 IHC HER2(-) samples, all but 2 were negative by qRT-PCR. One sample was positive by both qRT-PCR assays; one was positive by Oncotype Dx only. The expression levels determined by the qRT-PCR assays showed good correlation for ESR1 (r=0.85) and PGR (r=0.9). Conclusions: Concordance between qRT-PCR and IHC was 98.6% for ER and 97.7% for PR. Except for a single HER2 determination, there was 100% concordance between the two qRT-PCR assays. The discordant sample was HER2 (+) by multiplex qRT-PCR and “equivocal” by Oncotype Dx. Excellent correlation was also observed in the mRNA expression levels. The absence of HER2(+) and ER(-) samples are limitations of this study. These results suggest that qRT-PCR is a promising alternative method to IHC for determining hormone receptor status. Additional testing of samples with endocrine therapy outcomes including ER(-) samples would be beneficial. |
---|---|
AbstractList | Abstract only
47
Background: IHC is the present standard for measuring estrogen (ER) and progesterone receptor (PR) expression for breast cancer. However, the lack of concordance between testing laboratories and the critical patient treatment decisions made with results prompted ASCO/CAP to recommend guidelines and proficiency testing requirements to ensure accuracy. Quantitative RT-PCR (qRT-PCR) is an alternative method for ER and PR testing and while concordance with IHC has been reported, additional testing is merited. This study compares ER, PR and HER2 status determined by IHC and qRT-PCR. Methods: FFPE tissues of ER(+) tumors collected and tested at the Blumenthal Cancer Center were studied. Expression levels of ESR1, PGR, and ERBB2 were determined by a multiplex qRT-PCR TaqMan assay and by the Oncotype Dx assay. Pre-established cutpoints were used to determine positivity. Only samples with qRT-PCR and corresponding IHC data were used, resulting in 144 ER, 128 PR, and 107 HER2 comparisons. ESR1 and PGR expression levels determined by the two qRT-PCR assays were also compared. Results: Of the144 IHC ER(+) samples, 142 were positive and 2 were negative by both qRT-PCR assays. All 120 IHC PR(+) samples were positive by both qRT-PCR assays. Of the 8 IHC PR(-) samples, 5 were negative and 3 were positive by both qRT-PCR assays. Of the 107 IHC HER2(-) samples, all but 2 were negative by qRT-PCR. One sample was positive by both qRT-PCR assays; one was positive by Oncotype Dx only. The expression levels determined by the qRT-PCR assays showed good correlation for ESR1 (r=0.85) and PGR (r=0.9). Conclusions: Concordance between qRT-PCR and IHC was 98.6% for ER and 97.7% for PR. Except for a single HER2 determination, there was 100% concordance between the two qRT-PCR assays. The discordant sample was HER2 (+) by multiplex qRT-PCR and “equivocal” by Oncotype Dx. Excellent correlation was also observed in the mRNA expression levels. The absence of HER2(+) and ER(-) samples are limitations of this study. These results suggest that qRT-PCR is a promising alternative method to IHC for determining hormone receptor status. Additional testing of samples with endocrine therapy outcomes including ER(-) samples would be beneficial. |
Author | Chang, Monica Calhoun, Benjamin Kwok, Shirley Eberhard, David A. Sninsky, John J. Anderson, Steven M. Christopherson, Cindy Wang, Alice M. |
Author_xml | – sequence: 1 givenname: Cindy surname: Christopherson fullname: Christopherson, Cindy organization: Celera Corporation, Alameda, CA – sequence: 2 givenname: Monica surname: Chang fullname: Chang, Monica organization: Celera Corporation, Alameda, CA – sequence: 3 givenname: David A. surname: Eberhard fullname: Eberhard, David A. organization: University of North Carolina, Chapel Hill, NC – sequence: 4 givenname: John J. surname: Sninsky fullname: Sninsky, John J. organization: Celera Corporation, Alameda, CA – sequence: 5 givenname: Steven M. surname: Anderson fullname: Anderson, Steven M. organization: Laboratory Corporation of America, Research Triangle Park, NC – sequence: 6 givenname: Alice M. surname: Wang fullname: Wang, Alice M. organization: Celera Corporation, Alameda, CA – sequence: 7 givenname: Shirley surname: Kwok fullname: Kwok, Shirley organization: Celera Corporation, Alameda, CA – sequence: 8 givenname: Benjamin surname: Calhoun fullname: Calhoun, Benjamin organization: Blumenthal Cancer Center, Charlotte, NC |
BookMark | eNo1kFFLwzAYRYNMcJv-BvOoYOuXpF0y36RUNxg4ygTfQpomrGNtatIO9u_tUB8u5-VyuZwZmrSuNQjdE4gJBXg-aBdTIDRmEFMuw9B1xzjhV2hKUsojztN0gqbAGY2IYF83aBbCAYAkgqVTVGau6ZSvg2uxs7humqF1-zr0Tu9NM9Kf8cN6lT1i1Vb4e1BtX_eqr08GF7tomxUvOC-e8HbMpbDKC4q90abrncdhbA7hFl1bdQzm7o9z9PmW77JVtPl4X2evm0gTGI9aW2mTKrZYikSZxC4tMVosCDElVJZViukKqiUjhgNh2grNCRWlEEwlJWjN5oj_7mrvQvDGys7XjfJnSUBeVMlRlbyokgzkvyqZcPYDzV5iGg |
CitedBy_id | crossref_primary_10_1016_j_clbc_2020_04_012 crossref_primary_10_1186_s13058_015_0561_8 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1200/jco.2012.30.27_suppl.47 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 47 |
ExternalDocumentID | 10_1200_jco_2012_30_27_suppl_47 |
GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP AAYOK AAYXX ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AFFNX AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL C45 CITATION CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N9A O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY |
ID | FETCH-LOGICAL-c1027-ffdce5a36984ae4f9f1ec8611eb0df3da3cd0d931e7013cf8c7128b883a4b0cc3 |
ISSN | 0732-183X |
IngestDate | Fri Aug 23 03:16:39 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 27_suppl |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1027-ffdce5a36984ae4f9f1ec8611eb0df3da3cd0d931e7013cf8c7128b883a4b0cc3 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1200_jco_2012_30_27_suppl_47 |
PublicationCentury | 2000 |
PublicationDate | 2012-09-20 |
PublicationDateYYYYMMDD | 2012-09-20 |
PublicationDate_xml | – month: 09 year: 2012 text: 2012-09-20 day: 20 |
PublicationDecade | 2010 |
PublicationTitle | Journal of clinical oncology |
PublicationYear | 2012 |
SSID | ssj0014835 |
Score | 2.0991433 |
Snippet | Abstract only
47
Background: IHC is the present standard for measuring estrogen (ER) and progesterone receptor (PR) expression for breast cancer. However, the... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 47 |
Title | Comparison of immunohistochemistry (IHC) and quantitative RT-PCR: ER, PR, and HER2 receptor status |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nj9MwELXKIiEuCBYQsIB8QCtQ65DEbpxwW4WismhRVHWl3iLHsQUc0v1oD-XX8dMYx3Fi2EWwHBo1aT1KO08z48mbGYRepbXWpk0WSVPKCOOSkkxkgjCR1iysFXhFk4c8-ZzMT9nxaroajX54rKXtpgrk92vrSv5Hq3AN9GqqZG-g2V4oXID3oF84gobh-E86zv0hguOvptRj3TYQlm6MWxtAznOz9zcZ8vOtaNqqMsMXWixJkS9MSsCyIYqFo3LOZ4t4DKZQncGO3GQbNl164GoU21dWrhv5S4be61rQFXXlsP33Pu4S1caoDHShWaUuvgiPbj8-CvokUGOmbO8cgXh8HPgpC8P9yEgcepaN05iALVlZJ9RZ3phDqG979jrTTEMPgjEvL82kU8_c2madneO2J1dcQtxOu_4mTaVnFAc0DJygwC33m3D_5hx7yqLZLIGoEgSVRlBJw9IJKhm_hW7HPJsaUun7j5_651gstSNe3Q_uGIYg6O0f7siLj7xAZ3kf3et0i48s3B6gkWr20Z2TjoOxjw4L2-18N8HLoXjvcoIPcTH0Qd89RNUAT7zW-Dp44tcAzjcYMId9aGILzXd4tpjgAl7mCwaU2IESW1A-QqcfZst8TrqRHkRCJMuJ1rVUU0GTLGVCMZ3pSMk0iSJVhbWmtaCyDuuMRorD3kTqVHIIoCowJIJVoZT0Mdpr1o16gjClKSzXIqNUMq2MOF5FiUi5jBIIkp-i0P2R5Znt3FL-RYnPbr7kAN0dEP4c7W0utuoFhKmb6mWLhJ-d4JKu |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+immunohistochemistry+%28IHC%29+and+quantitative+RT-PCR%3A+ER%2C+PR%2C+and+HER2+receptor+status&rft.jtitle=Journal+of+clinical+oncology&rft.au=Christopherson%2C+Cindy&rft.au=Chang%2C+Monica&rft.au=Eberhard%2C+David+A.&rft.au=Sninsky%2C+John+J.&rft.date=2012-09-20&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=30&rft.issue=27_suppl&rft.spage=47&rft.epage=47&rft_id=info:doi/10.1200%2Fjco.2012.30.27_suppl.47&rft.externalDBID=n%2Fa&rft.externalDocID=10_1200_jco_2012_30_27_suppl_47 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |